CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This study seeks to examine the feasibility and safety of the administration of autologous T
cells that have been modified through the introduction of a chimeric antigen receptor
targeting the B cell surface antigen CD19 following administration of chemotherapy
lymphodepletion regimen in children and adults with relapsed/refractory B cell malignancies.